Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Amgen Inc.

Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Multiple Myeloma


Release Date: February 28, 2018
Expiration Date: February 28, 2019
Media: Internet - based

 

Activity Overview

This online activity is designed to update physicians on data presented at a major oncology meeting, held in Atlanta, GA, in December 2017, to facilitate critical assessment and, when appropriate, clinical integration of new evidence. The activity reviews 4 abstracts selected by the program faculty, Shaji Kumar, MD, as the most clinically relevant from the meeting. For each abstract, a short summary of key clinical data is accompanied by faculty commentary that provides insight into how new data fit into the current field, and how clinicians can apply these findings to their clinical practice to improve patient care. Interactive questions are interspersed throughout the activity to enable engagement, learning, and self-assessment.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen Inc.

CME Activity Table of Contents

  • Updated Efficacy and Safety From the Phase III Study of Daratumumab, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  • Updated Results on the Use of CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
  • Final Overall Survival From a Phase III Study of Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  • An Integrated Analysis From Multiple Phase I/II Studies of Ixazomib in Patients With Newly Diagnosed Multiple Myeloma

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This activity is directed toward medical oncologists who treat patients with multiple myeloma. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with multiple myeloma are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Detail the design, efficacy, and safety endpoints of ongoing and recently completed clinical trials in patients with multiple myeloma
  • Elaborate on key efficacy and safety results concerning the use of novel strategies in patients with multiple myeloma and how to incorporate them into practice
  • Place presented clinical trial evidence in the context of evolving treatment paradigms and strategies in the management of patients with multiple myeloma

Faculty, Staff, and Planners' Disclosures

Faculty

Shaji Kumar, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, MN
 

Disclosure:Consultant: Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc., Vaniam Group LLC, AbbVie, Alexion; Research Support: Kite, Regeneron, Acerta; Consultant/Research Support: Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

 

PER Pulse ™ Recap

PER Pulse Recap (1 of 3)

Updated Results From the Phase III POLLUX Trial in Relapsed or Refractory Multiple Myeloma
 
This first of 3 PER Pulse™ Recaps from this program focuses on the use of daratumumab, an immunomodulatory agent, in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma (RRMM).
 
Dr. Kumar detailed the latest clinical readouts from the phase III POLLUX trial investigating this combination in patients with RRMM:
 
  • This phase III, open-label, active-controlled, parallel-group, multicenter trial randomized 569 patients with RRMM to receive lenalidomide and dexamethasone alone or in combination with daratumumab.
  • The primary endpoint of this trial was progression-free survival (PFS). Secondary endpoints included time to disease progression, very good partial response (VGPR) rate, minimal residual disease (MRD) status, objective response rate (ORR), and overall survival (OS), as well as other measures.
  • With a median follow-up of 32.9 months, median PFS for patients on the daratumumab arm had not yet been reached. For patients on the control arm, median PFS was reported to be 17.5 months (HR, 0.44; 95% CI, 0.34-0.55; P<.0001). The 30-month PFS rate was 58% for patients in the experimental arm compared with 35% for patients in the control arm.
  • The ORR for patients receiving daratumumab was 93% (55% complete response, 26% VGPR, 13% partial response) compared with 76% for patients on the control arm. The MRD-negative rates were 4 times greater for patients receiving daratumumab compared with those on the control arm.
 
For additional information and commentary on this topic, as well as audio and supporting text, visit http://www.gotoper.com/online-cme-activities/csac/cancer-summaries-and-commentaries-update-from-atlanta--advances-in-the-treatment-of-multiple-myeloma.
 
For information on other topics, visit gotoper.com.


PER Pulse Recap (2 of 3)

Final Results From the Phase III ASPIRE Trial Investigating Carfilzomib
 
This second of 3 PER Pulse™ Recaps from this program focuses on the use of carfilzomib, a proteasome inhibitor, in combination with lenalidomide and dexamethasone for the treatment of RRMM.
 
Dr. Kumar detailed the final clinical readout from the phase III ASPIRE trial investigating this combination in patients with RRMM:
 
  • The open-label, multicenter, phase III ASPIRE trial randomized patients to receive either lenalidomide and dexamethasone alone or in combination with carfilzomib.
  • Previous reports have demonstrated that the addition of carfilzomib to lenalidomide and dexamethasone resulted in an improved median PFS of 26.3 months compared with 17.6 months in the control arm. Overall, addition of carfilzomib reduced the risk of progression by 31%.
  • In this report, median OS was 48.3 months (95% CI, 42.4-52.8) for patients receiving carfilzomib compared with 40.4 months (95% CI, 33.6-44.4) for patients in the control arm. Median OS was 11.4 months longer for patients receiving carfilzomib who previously had received only 1 prior line of therapy and 6.5 months longer for patients receiving ≥2 prior lines.
  • Overall, treatment with carfilzomib in combination with lenalidomide and dexamethasone resulted in an improved median OS of 7.9 months and a reduction in risk of death of 21%.
 
For additional information and commentary on this topic, as well as audio and supporting text, visit http://www.gotoper.com/online-cme-activities/csac/cancer-summaries-and-commentaries-update-from-atlanta--advances-in-the-treatment-of-multiple-myeloma.
 
For information on other topics, visit gotoper.com.


PER Pulse Recap (3 of 3)

Integrated Analysis of Ixazomib in Newly Diagnosed Multiple Myeloma
 
This third and final PER Pulse™ Recap from this program focuses on the use of ixazomib, an oral proteasome inhibitor, in various combinations and schedules for the treatment of newly diagnosed multiple myeloma (NDMM).
 
Dr. Kumar detailed the clinical analysis from 4 phase I/II trials investigating combinations of ixazomib in the first-line setting for NDMM:
 
  • Following results from the TOURMALINE-MM1 trial, ixazomib was approved in combination with lenalidomide and dexamethasone for patients who received at least 1 prior line of therapy in 2015. The triplet improved PFS by 6 months compared with lenalidomide and dexamethasone alone (20.6 months vs 14.7 months).
  • This abstract integrates results from 4 phase I/II trials investigating ixazomib in NDMM: a phase I/II dose-escalation trial in combination with lenalidomide and dexamethasone; a dose-escalation phase I/II study in combination with lenalidomide and dexamethasone, in which ixazomib was administered twice weekly; a dose-escalation phase I/II study in combination with melphalan and prednisone; and a phase II study in combination with cyclophosphamide and dexamethasone for patients with either NDMM or RRMM.
  • Overall, 121 patients received ixazomib maintenance therapy across all 4 trials. The pooled median PFS was 33.8 months from time of study entry and 21.4 months from start of maintenance monotherapy. Median PFS from the start of maintenance monotherapy was longer for the 2 lenalidomide/dexamethasone studies than for the melphalan/prednisone study; median PFS for the fourth study had not yet been reached.
  • Ongoing phase III investigations include a placebo-controlled investigation into ixazomib in combination with lenalidomide and dexamethasone (NCT01850524) and ixazomib single-agent maintenance therapy for patients not undergoing stem cell transplantation (NCT02312258).
 
For additional information and commentary on this topic, as well as audio and supporting text, visit http://www.gotoper.com/online-cme-activities/csac/cancer-summaries-and-commentaries-update-from-atlanta--advances-in-the-treatment-of-multiple-myeloma.
 
For information on other topics, visit gotoper.com.








Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By